Progress Toward All-Oral, Interferon-Free Therapy for HCV Genotype 1 Infection

Regimens tested in open-label studies achieved high virologic response with low resistance and few adverse effects.

Interferon is still currently required for treating hepatitis C virus (HCV) genotype 1 infection. Now, investigators report findings of two new studies evaluating interferon-free regimens for these patients.

In an open-label study, Sulkowski and colleagues evaluated daclatasvir (an NS5A inhibitor; 60 mg daily) plus sofosbuvir (an NS5B inhibitor; 400 mg daily) with or without ribavirin for 24 weeks in patients with genotype 1 infection (44 treatment-naive and 41 treatment-experienced with telaprevir-based or boceprevir-based regimens). Another 82 treatment-naive patients received therapy for 12 weeks. Sustained virologic response (SVR) at 12 weeks posttreatment was 98% and did not vary by ribavirin use, HCV subtype, or IL28B genotype.

In a pha…

Reviewing Author

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Progress Toward All-Oral, Interferon-Free Therapy for HCV Genotype 1 Infection

Topics

Reviewing Author